Robuta

https://pmc.ncbi.nlm.nih.gov/articles/PMC5993548/ Enzymes as Immunotherapeutics - PMC Enzymes are attractive as immunotherapeutics because they can catalyze shifts in the local availability of immunostimulatory and immunosuppressive signals.... enzymesimmunotherapeuticspmc https://imcyse.com/ Imcyse - specific active immunotherapeutics specificactiveimmunotherapeutics https://www.fxempire.com/stocks/mltx/chart MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Stock Live Chart | FXEmpire View live MoonLake Immunotherapeutics Class A Ordinary Shares stock chart to track the latest price changes. MLTX price chart, real-time data, technical... class aordinary shareslive chartmoonlakeimmunotherapeutics https://www.fiercebiotech.com/biotech/pionyr-immunotherapeutics-gains-meaty-62m-series-b Pionyr Immunotherapeutics gains meaty $62M series B | Fierce Biotech Dec 13, 2017 - California startup Pionyr is using $62 million of VC-backed funding to target antibodies in the tumor microenvironment. series bpionyrimmunotherapeuticsgainsmeaty https://www.globenewswire.com/de/news-release/2025/11/05/3181261/0/en/moonlake-immunotherapeutics-reports-third-quarter-2025-financial-results-and-announces-new-data-from-clinical-trials-of-its-nanobody-sonelokimab.html MoonLake Immunotherapeutics Reports Third Quarter 2025 Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a... third quartermoonlakeimmunotherapeuticsreports2025 https://www.biospace.com/press-releases/ose-immunotherapeutics-to-present-groundbreaking-extension-period-data-on-lusvertikimab-at-ddw-2025 OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025... https://www.biospace.com/ose-immunotherapeutics-presents-preclinical-data-on-mrna-therapeutic-platform-for-the-treatment-of-inflammatory-and-autoimmune-disorders-at-the-focis-annual-meeting-san-francisco-june-18-21 OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of... Jul 17, 2024 - OSE Immunotherapeutics SA, presented a poster on preclinical data on its mRNA therapeutic platform for the treatment of inflammatory and autoimmune disorders... https://www.eib.org/fr/registers/all/255758106 OSE IMMUNOTHERAPEUTICS (EGFF) (COVID-19) oseimmunotherapeuticsegffcovid19 https://www.globenewswire.com/de/news-release/2026/01/08/3215344/0/en/moonlake-immunotherapeutics-announces-positive-outcome-from-type-b-meeting-with-u-s-fda-and-announces-investor-day.html MoonLake Immunotherapeutics Announces Positive Outcome from MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence... positive outcomemoonlakeimmunotherapeuticsannounces https://www.biospace.com/pionyr-immunotherapeutics-initiates-phase-1-clinical-study-of-py314 PIONYR Immunotherapeutics Initiates Phase 1 Clinical Study Of PY314 - BioSpace Nov 18, 2020 - Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body's antitumor immunity by altering the... phase 1clinical studypionyrimmunotherapeuticsinitiates https://www.terrapinn.com/conference/world-vaccine-immunotherapy-congress-west-coast/exhibitor-eyam-vaccines-and-immunotherapeutics.stm Eyam Vaccines and Immunotherapeutics, exhibiting at | Vaccine West Coast eyamvaccinesimmunotherapeuticsexhibitingwest https://www.prnewswire.com/news-releases/scinai-immunotherapeutics-announces-2-61-million-private-placement-financing-302752848.html Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative... private placementimmunotherapeuticsannounces261 https://www.biospace.com/press-releases/ose-immunotherapeutics-to-present-anti-il-7r-lusvertikimab-phase-2-induction-results-in-ulcerative-colitis-at-20th-congress-of-ecco OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative... https://www.frontiersin.org/research-topics/69174/guiding-gene-editing-to-deliver-precision-based-immunotherapeutics/articles Frontiers | Guiding Gene Editing to Deliver Precision Based Immunotherapeutics Gene editing is a powerful technique which opens the possibility of genetic therapies which can rectify mutations which normally lead to disease. The use of ... gene editingfrontiersguidingdeliverprecision https://elixiron.com/ Elixiron Immunotherapeutics (Cayman) Limited Elixiron Immunotherapeutics employs advances in translational medicine to identify targets from clinical observations, and various drug modalities including... immunotherapeuticscaymanlimited https://www.onechaintx.com/ OneChain Immunotherapeutics CAR-T Immunotherapies against hematological malignancies immunotherapeutics https://www.fiercebiotech.com/keyword/ose-immunotherapeutics OSE Immunotherapeutics | Fierce Biotech oseimmunotherapeuticsfiercebiotech https://www.globenewswire.com/news-release/2026/01/08/3215344/0/en/moonlake-immunotherapeutics-announces-positive-outcome-from-type-b-meeting-with-u-s-fda-and-announces-investor-day.html MoonLake Immunotherapeutics Announces Positive Outcome from MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence... positive outcomemoonlakeimmunotherapeuticsannounces https://www.mondaq.com/life-sciences-biotechnology-nanotechnology/1608110/deal-ticker-kellerhals-carrard-advised-moonlake-immunotherapeutics-on-debt-financing-with-hercules-capital-inc Deal Ticker: Kellerhals Carrard Advised MoonLake Immunotherapeutics On Debt Financing With Hercules... MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a Swiss clinical-stage biotechnology company focused on creating next-level therapies for inflammatory... https://www.biospace.com/ose-immunotherapeutics-provides-business-and-corporate-update OSE Immunotherapeutics Provides Business and Corporate Update - BioSpace May 31, 2024 - OSE Immunotherapeutics Provides Business and Corporate Update Three pharmaceutical agreements signed during the last three months. business and corporateoseimmunotherapeuticsprovidesupdate https://jvacimmuno.com/ Journal of Vaccines & Immunotherapeutics - Home Apr 22, 2026 - Journal of Vaccines and Immunotherapeutics Review Latest Developments in the field of Vaccines and Immunotherapy. Print ISSN : Awaited | Online ISSN : Awaited... journalvaccinesimmunotherapeutics https://immunovac.bioconnectiowa.org/ Vaccines, Diagnostics, and Immunotherapeutics - A Bioscience Platform in Iowa Aug 11, 2023 - A partnership between Iowa State University, University of Iowa and BioConnect Iowa. The State of Iowa is committed to the development of the vaccine and... vaccinesdiagnosticsimmunotherapeuticsbioscienceplatform https://www.finanznachrichten.de/nachrichten-2025-01/64414834-ose-immunotherapeutics-and-scienta-lab-establish-strategic-partnership-to-leverage-artificial-intelligence-in-precision-immunotherapy-399.htm OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial... OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy Nantes and Paris -... strategic partnershiposeimmunotherapeuticslab https://www.ascendobiotech.com/ Novel Immunotherapeutics & Innate Immune Research | Ascendo Biotechnology May 5, 2026 - Ascendo Biotechnology is developing novel cancer immunotherapies and functional cures for chronic viral infections through targeting of the innate immune system novelimmunotherapeuticsinnateimmuneresearch https://www.biospace.com/moonlake-immunotherapeutics-to-host-capital-markets-day-in-new-york-and-virtually-today MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today - BioSpace Apr 19, 2023 - MoonLake Immunotherapeutics AG will host today its Capital Markets Day for investors and analysts in New York and virtually. https://www.globenewswire.com/news-release/2025/05/21/3085998/0/en/OSE-Immunotherapeutics-Announces-Strategic-Collaboration-to-Pioneer-Novel-mRNA-Technologies.html OSE Immunotherapeutics Announces Strategic Collaboration to OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies OSE Immunotherapeutics to lead French consortium with Inside... strategic collaborationoseimmunotherapeuticsannounces https://ivri.berkeley.edu/ Immunotherapeutics and Vaccine Research Initiative (IVRI) vaccine researchimmunotherapeuticsinitiativeivri https://kalivir.com/ main - KaliVir Immunotherapeutics Nov 19, 2025 - multiple therapies, one virus.KALIVIR is developing cutting edge, next-generation oncolytic viral immunotherapy programs for treatment of cancer. LEARN MORE... mainimmunotherapeutics https://www.businesswire.com/news/home/20230705871911/en/OSE-Immunotherapeutics-Announces-for-Lusvertikimab-its-Anti-IL-7-Receptor-Antagonist OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist: OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist il 7 receptoroseimmunotherapeuticsannounces https://www.biospace.com/scinai-immunotherapeutics-granted-extension-by-nasdaq-hearing-panel-to-regain-compliance-with-continued-listing-requirements Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with... https://www.biospace.com/ose-immunotherapeutics-provides-an-update-on-the-first-positive-results-and-clinical-development-of-covepit-its-multi-target-t-cell-anti-covid-vaccine OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of... Nov 30, 2021 - OSE Immunotherapeutics announces the positive analysis of the first data of CoVepiT, its prophylactic vaccine candidate against COVID-19, in particular... https://www.prnewswire.com/news-releases/pharmathene-and-altimmune-announce-merger-to-create-immunotherapeutics-company-targeting-infectious-diseases-300393398.html PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious... /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced... announcemerger https://www.macrotrends.net/stocks/charts/SCNI/scinai-immunotherapeutics/net-worth Scinai Immunotherapeutics Net Worth 2016-2025 | SCNI | MacroTrends Interactive chart of historical net worth (market cap) for Scinai Immunotherapeutics (SCNI) over the last 10 years. How much a company is worth is typically... net worthimmunotherapeutics20162025macrotrends https://www.businesswire.com/news/home/20210521005081/en/Michael-Andreeff-M.D.-Ph.D-to-Join-the-Scientific-Advisory-Board-of-Brooklyn-ImmunoTherapeutics-Inc. Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics,... Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc. the scientific advisory board https://www.biospace.com/brooklyn-immunotherapeutics-named-to-nasdaq-biotechnology-index Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index - BioSpace Dec 14, 2021 - Brooklyn ImmunoTherapeutics, Inc today announces that Brooklyn has been named to be part of the Nasdaq Biotechnology Index (Nasdaq:NBI), effective December 20,... nasdaq biotechnology indexbrooklynimmunotherapeuticsnamed https://hditx.de/ HDITx | Antibody-based Immunotherapeutics Fighting the human herpes simplex virus and tumour diseases - Heidelberg ImmunoTherapeutics introduces immunotherapeutic agents into clinical use antibodybasedimmunotherapeutics https://www.globenewswire.com/news-release/2025/11/05/3181261/0/en/moonlake-immunotherapeutics-reports-third-quarter-2025-financial-results-and-announces-new-data-from-clinical-trials-of-its-nanobody-sonelokimab.html MoonLake Immunotherapeutics Reports Third Quarter 2025 Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a... third quartermoonlakeimmunotherapeuticsreports2025 https://www.newsfilecorp.com/release/270731/MLTX-INVESTOR-REPORT-BFA-Law-Alerts-MoonLake-Immunotherapeutics-Investors-that-a-Class-Action-Lawsuit-was-Filed-Against-the-Company-for-Fraud-and-Urges-You-to-Contact-the-Firm MLTX INVESTOR REPORT: BFA Law Alerts MoonLake Immunotherapeutics Investors that a Class Action... https://www.home.saxo/fr-ch/markets/stocks/scni_new-xnas Scinai Immunotherapeutics Ltd - ADR action | Saxo Bank Suisse saxo bankimmunotherapeuticsltdadraction https://www.home.saxo/nb-no/markets/stocks/scni_new-xnas Scinai Immunotherapeutics Ltd - ADR aksje | Saxo Bank immunotherapeuticsltdadraksjesaxo https://www.paradoximmuno.com/ Paradox Immunotherapeutics Rare disease treatment paradoximmunotherapeutics https://www.ig.com/nl/aandelen/markten-aandelen/innate-immunotherapeutics-limited Koers Innate Immunotherapeutics Limited | Aandeel Innate Immunotherapeutics Limited | Innate... Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary,... [NL] innate immunotherapeuticskoerslimitedaandeel https://www.lifordi.com/ Home - Lifordi Immunotherapeutics immunotherapeutics https://www.prnewswire.com/news-releases/mltx-investor-alert-bronstein-gewirtz--grossman-llc-announces-that-moonlake-immunotherapeutics-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302587145.html MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics... investor alertmltxbronsteingewirtz https://www.newsfilecorp.com/release/289695/Advancements-in-Novel-Immunotherapeutics-in-The-Oncology-Battle Advancements in Novel Immunotherapeutics in The Oncology Battle Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry... advancementsnovelimmunotherapeuticsoncologybattle https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.673699/full Frontiers | Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for... Conventional vaccinations and immunotherapies have encountered major roadblocks in preventing infectious diseases like HIV, influenza, and malaria. This chal... infectious diseases https://www.prnewswire.com/news-releases/stockholder-alert-robbins-llp-informs-moonlake-immunotherapeutics-stockholders-that-a-class-action-lawsuit-was-filed-against-the-company-302585604.html Stockholder Alert: Robbins LLP Informs MoonLake Immunotherapeutics Stockholders that a Class Action... /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired MoonLake... https://www.home.saxo/en-mena/markets/stocks/scni_new-xnas Scinai Immunotherapeutics Ltd - ADR stock | Saxo Bank immunotherapeuticsltdadrstocksaxo https://www.prnewswire.com/news-releases/multicell-immunotherapeutics-and-oxis-biotech-sign-antibody-drug-conjugate-rd-product-license-and-commercialization-agreement-300049682.html MultiCell Immunotherapeutics And Oxis Biotech Sign Antibody-Drug Conjugate R&D, Product License And... /PRNewswire/ -- MultiCell Immunotherapeutics, Inc. (MCIT), a majority owned subsidiary of MultiCell Technologies, Inc. (OTC: MCET) announced today it has... antibody drug conjugate https://kalivirimmunotx.com/ KALIVIR Immunotherapeutics immunotherapeutics https://www.businesswire.com/news/home/20240327991047/en/OSE-Immunotherapeutics-Reports-Full-Year-2023-Financial-Results-and-Provides-Business-Strategy-Update OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy... OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update. full year2023 financial